글로벌 연구동향
핵의학
- 2019년 11월호
[Clin Nucl Med.] Risk Factors for Indeterminate Response After Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer.아주의대 / 정유진, 안영실*
- 출처
- Clin Nucl Med.
- 등재일
- 2019 Sep
- 저널이슈번호
- 44(9):714-718. doi: 10.1097/RLU.0000000000002653.
- 내용
Abstract
PURPOSE:
We investigated the risk factors of indeterminate response (IDR) in patients who underwent recombinant human thyroid-stimulating hormone (rhTSH)-aided radioactive iodine therapy (RAIT).METHODS:
A total of 128 patients with papillary thyroid cancer were included in this retrospective study. The patients were classified into excellent response and IDR groups based on follow-up diagnostic whole-body scintigraphy (WBS) and TSH-stimulated thyroglobulin (Tg). Indeterminate response was defined as the presence of a faint uptake in the thyroid bed on the diagnostic WBS or a TSH-stimulated Tg detectable, but less than 10 ng/mL. Parameters that act as significant risk factors for IDR, including age, sex, stage, surgeon, time interval between surgery and RAIT, post-treatment WBS finding, urine iodine-to-creatinine ratio, TSH-unstimulated Tg, and rhTSH-stimulated Tg, were analyzed using a Cox proportional hazards regression method.RESULTS:
After treatment, 64 patients showed IDR. Recombinant human TSH-stimulated Tg was the only independent risk factor for predicting IDR. Patients with an rhTSH-stimulated Tg greater than 2 ng/mL prior to RAIT were 3.75 times more likely (95% confidence interval, 1.61-8.72) to have an IDR than those with a lower rhTSH-stimulated Tg (≤2 ng/mL).CONCLUSIONS:
Pre-RAIT TSH-stimulated Tg levels are a risk factor for IDR after RAIT.
Author informationJeong E1, Yoon JK1, Lee SJ1, Soh EY2, Lee J2, An YS1.
1
From the Departments of Nuclear Medicine and Molecular Imaging.
2
Surgery, Ajou University School of Medicine, Suwon, Korea.
- 덧글달기
- 이전글 [Clin Nucl Med.] Clinical Utility of 18F-Florbetaben PET for Detecting Amyloidosis Associated With Multiple Myeloma: A Prospective Case-Control Study.
- 다음글 [Clin Nucl Med.] A Stepwise Approach to Identify the Clinical Role of 18F-FDG PET/CT in Patients With Suspicious Bone Metastasis From an Unknown Primary Site.